Eledon Pharmaceuticals approaches its May 19 Q1 earnings report with a notable shift in positioning: short sellers have been covering, the stock is up 26% in a month, and the borrow market remains undemanding — a setup that looks more constructive than punishing, even as the ORTEX short score holds elevated at 71.
The most meaningful move in the lending market is the retreat in short interest. After running near 9.8 million shares in early April, estimated short interest has fallen sharply to just under 8 million shares, now 10.6% of the free float — a drop of roughly 7% on the week and 17% over the past month. Borrow availability is not tight; at 64% utilization, well off the 52-week high of 64.7% touched just a session earlier, there is adequate supply remaining in the lending pool. Cost to borrow has edged up around 30% over the month to 0.70% annualised — still cheap in absolute terms. This is not a borrow squeeze. Shorts are leaving on their own terms.
Options positioning reinforces the less-defensive tone. The put/call ratio has eased to 0.84, slightly below its 20-day average of 0.89 and roughly 0.8 standard deviations below that mean. Recall that in late March and early April, the PCR ran well above 1.0 before collapsing to near-zero in a burst of call activity around April 9-10. That swing accounts for the wide 52-week range — from 0.007 to 2.67 — and the current reading reflects a more neutral stance rather than pronounced directional conviction either way.
The Street's view on Eledon is unanimously bullish but dated. All coverage carries Buy ratings. The most recent price target on record is $8.00, set by Guggenheim in November 2025 after trimming from $9.00, with Craig-Hallum having initiated at $12.00 in July 2025. At a $3.90 close, the analyst consensus implies more than 100% upside — but this data is now roughly six months old and should be treated with caution given the company's clinical-stage status and intervening price moves. No analyst revisions have been reported in 2026. The bear case centres on cash burn — a $17.5 million net loss in Q3 2025 — alongside clinical trial risk and dilution risk from ongoing capital needs. The bull case rests on tegoprubart's Phase 2 BESTOW data showing a cleaner tolerability profile than tacrolimus in transplant patients, positioning the compound competitively in the transplantation and autoimmune disease markets.
Institutional ownership offers some conviction signal. BlackRock added 754,000 shares as of April 30. Vanguard added 772,000 as of March 31. Several smaller healthcare-focused funds — Defilade, ADAR1, CHI Advisors — appear to have initiated entirely new positions through end-2025. BVF Partners, a specialist biotech long-short firm, remains the largest holder at 8.4% of shares, unchanged since year-end. The aggregate holder count sits at 96 institutions.
Earnings history is consistent in one direction: the stock has fallen on the day of each of the last four reported events, with drops ranging from 3% to 8%. The five-day picture is more mixed — two of those releases saw a recovery over the subsequent week, two did not. With Q1 results due May 19, that pattern is the primary variable worth tracking into next week.
See the live data behind this article on ORTEX.
Open ELDN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
